EDOXABAN SWITCHING STUDY FOR APIXABAN

EDOXABAN SWITCHING STUDY FOR APIXABAN - EDOXABAN SWITCHING STUDY FOR APIXABAN

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36871

Enrollment

Registered

2012-09-05

Start date

2012-09-24

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood clotting Thrombosis

Interventions

Treatment A: single oral doses of 60 mg edoxaban (administered as 2 x 30 mg) on Days 1 to 4 (all days inclusive) Treatment B: 5 mg apixaban twice daily (bid) (administered as 2 x2.5 mg) every 12 hou

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy male and female (negative pregnancy test) Age: 18-45 years (inclusive) BMI: 18.0 - 30.0 (inclusive)

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters blood (males) or 1,0 liters blood (female) in the 10 months preceding the start of the study.

Design outcomes

Primary

Measure	Time frame
Pharmacodynamics, Pharmacokinetics, Safety	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)